Micro-costing diagnostics in oncology
| Autor: | Edwin Cuppen, Katrien Grünberg, Valesca P. Retèl, Clémence T. B. Pasmans, Veerle M.H. Coupé, Geert W.J. Frederix, Stefan M. Willems, Eiko K. de Jong, Elisabeth M. P. Steeghs, Bastiaan B. J. Tops, Ed Schuuring, Ewart de Bruijn, Marjolijn J. L. Ligtenberg, Hans van Snellenberg |
|---|---|
| Přispěvatelé: | CCA - Cancer Treatment and quality of life, APH - Methodology, Epidemiology and Data Science, CCA - Imaging and biomarkers, Pathology, Health Technology & Services Research, Targeted Gynaecologic Oncology (TARGON), Damage and Repair in Cancer Development and Cancer Treatment (DARE) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Total cost Colorectal cancer Single gene Computational biology Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] Micro-costing symbols.namesake Neoplasms medicine Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14] standard diagnostic techniques Capital cost Humans Medical physics Pharmacology (medical) Genetic Testing Precision Medicine Activity-based costing Selection (genetic algorithm) health care economics and organizations Netherlands Sanger sequencing Whole genome sequencing DOCETAXEL whole genome sequencing business.industry MUTATIONS Health Policy Cancer NIVOLUMAB General Medicine personalized medicine medicine.disease CANCER Docetaxel Micro costing oncology symbols Costs and Cost Analysis Personalized medicine Nivolumab business medicine.drug |
| Zdroj: | Expert Review of Pharmacoeconomics and Outcomes Research, 21, 3, pp. 413-414 Expert Review of Pharmacoeconomics and Outcomes Research, 21(3), 413-414. Taylor and Francis Ltd. Pasmans, C T B, Tops, B B J, Steeghs, E M P, Coupé, V M H, Grünberg, K, de Jong, E K, Schuuring, E M D, Willems, S M, Ligtenberg, M J L, Retèl, V P, van Snellenberg, H, de Bruijn, E, Cuppen, E & Frederix, G W J 2021, ' Micro-costing diagnostics in oncology : from single-gene testing to whole-genome sequencing ', Expert Review of Pharmacoeconomics and Outcomes Research, vol. 21, no. 3, pp. 413-414 . https://doi.org/10.1080/14737167.2021.1917385 Expert Review of Pharmacoeconomics and Outcomes Research, 21, 413-414 Expert Review of Pharmacoeconomics and Outcomes Research, 21(3), 413-414. Taylor & Francis Expert review of pharmacoeconomics & outcomes research, 21(3), 403-414. Taylor & Francis Group |
| ISSN: | 1473-7167 |
| DOI: | 10.1080/14737167.2021.1917385 |
| Popis: | PurposePredictive diagnostics play an increasingly important role in personalized medicine for cancer treatment. Whole genome sequencing (WGS) based treatment selection is expected to rapidly increase worldwide. Detailed and comparative cost analyses of diagnostic techniques are an essential element in decision-making. This study aimed to calculate and compare the total cost of currently used diagnostic techniques and of WGS in treatment of non-small cell lung carcinoma (NSCLC), melanoma, colorectal cancer (CRC) and gastrointestinal stromal tumor (GIST) in the Netherlands.MethodsThe activity-based costing (ABC) method was conducted to calculate the total cost of included diagnostic techniques based on data provided by Dutch pathology laboratories and the Dutch centralized cancer WGS facility. Costs were allocated to four categories: capital costs, maintenance costs, software costs and operational costs. Outcome measures were total cost per cancer patient per included technique, and the total cost per cancer patient per most commonly applied technique (combination) for each cancer type.ResultsThe total cost per cancer patient per technique varied from € 58 (Sanger sequencing, 3 amplicons) to € 4738 (paired tumor-normal WGS). The operational costs accounted for the vast majority over 90 % of the total per cancer patient technique costs. The most important operational cost drivers were consumables followed by personnel (for sample preparation and primary data analysis).ConclusionThis study outlined in detail all costing aspects and cost prices of current and new diagnostic modalities used in treatment of NSCLC, melanoma, CRC and GIST in the Netherlands. Detailed cost differences and value comparisons between these diagnostic techniques enable future economic evaluations to support decision-making on implementation of WGS and other diagnostic modalities in routine clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|